Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508654 | 0.84 | MEN1 (0.51) | DBHKCNH2TLR8LMNAL3MBTL1 | |
| SCHEMBL10337115 | 0.79 | DBH (0.44) | DBHLMNAL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL1126356 | 0.78 | HSD17B10 (0.51) | KCNH2TLR8LMNAL3MBTL1MEN1 | |
| SCHEMBL13720308 | 0.77 | MAPT (0.45) | DBHKCNH2LMNAL3MBTL1MEN1 | |
| SCHEMBL7506449 | 0.77 | LMNA (0.40) | KCNH2TLR8TYMPLMNAL3MBTL1 | |
| SCHEMBL3979814 | 0.76 | KCNH2 (0.50) | DBHKCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3979066 | 0.76 | MAPT (0.44) | DBHKCNH2LMNAL3MBTL1MEN1 | |
| SCHEMBL7670390 | 0.75 | ALDH1A1 (0.44) | DBHKCNH2TLR8TYMPLMNA | |
| SCHEMBL7686598 | 0.75 | RAB9A (0.48) | DBHKCNH2TLR8TYMPLMNA | |
| SCHEMBL7499950 | 0.75 | LMNA (0.68) | LMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572921-B2 | Substituted benzylimidazoles useful for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| EP-1869012-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| WO-2006107923-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252811-A1 | SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES | IL4I1, NFKBIA, BRD4 | DBH 2139/4885KCNH2 3738/4885TLR8 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.